Johnson & Johnson (JNJ) stock
Close on Nov 18, 2026Market cap $656.47BP/E 41.4Yield 1.88%
Earnings
Johnson & Johnson's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Quarterly results
Revenue and earnings per share from each of Johnson & Johnson's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Adj. EPS | Source |
|---|---|---|---|---|---|---|
| Q4 FY2026ended Dec 28, 2026 | Jan 20, 2027Expected | – | – | – | – | – |
| Q3 FY2026ended Sep 27, 2026 | Oct 13, 2026before the open | $25.40B | +5.8% | $0.09 | $2.59 | Release |
| Q2 FY2026ended Jun 28, 2026 | Jul 15, 2026before the open | – | – | – | – | Release |
| Q1 FY2026ended Mar 29, 2026 | Apr 14, 2026before the open | $24.06B | +9.9% | $2.14 | $2.70 | Release |
| Q4 FY2025ended Dec 28, 2025 | Jan 21, 2026before the open | $24.60B | +9.3% | $2.10 | $2.46 | Release |
| Q3 FY2025ended Sep 28, 2025 | Oct 14, 2025before the open | $24.00B | +6.7% | $2.12 | $2.80 | Release |
| Q2 FY2025ended Jun 29, 2025 | Jul 16, 2025before the open | $23.74B | +6.0% | $2.29 | $2.77 | Release |
| Q1 FY2025ended Mar 30, 2025 | Apr 15, 2025before the open | $21.89B | +2.3% | $4.54 | $2.77 | Release |
| Q4 FY2024ended Dec 29, 2024 | Jan 22, 2025before the open | $22.50B | +5.1% | $1.41 | $2.04 | Release |
| Q3 FY2024ended Sep 29, 2024 | Oct 15, 2024before the open | $22.50B | +5.1% | $1.11 | $2.42 | Release |
| Q2 FY2024ended Jun 30, 2024 | Jul 17, 2024before the open | $22.40B | -12.2% | $1.93 | $2.82 | Release |
| Q1 FY2024ended Mar 31, 2024 | Apr 16, 2024before the open | $21.40B | -13.4% | $2.20 | $2.71 | Release |
| Q4 FY2023ended Dec 31, 2023 | Jan 23, 2024before the open | $21.40B | -9.7% | $1.70 | $2.29 | Release |
| Q3 FY2023ended Oct 1, 2023 | Oct 17, 2023before the open | $21.40B | -10.1% | $1.69 | $2.66 | Release |
| Q2 FY2023ended Jul 2, 2023 | Jul 20, 2023before the open | $25.50B | +6.3% | $1.96 | $2.80 | Release |
| Q1 FY2023ended Apr 2, 2023 | Apr 18, 2023before the open | $24.70B | +5.6% | -$0.03 | $2.68 | Release |
| Q4 FY2022ended Jan 1, 2023 | Jan 24, 2023before the open | $23.70B | -4.4% | $1.33 | $2.35 | Release |
| Q3 FY2022ended Oct 2, 2022 | Oct 18, 2022before the open | $23.80B | +2.1% | $1.68 | $2.55 | Release |
| Q2 FY2022ended Jul 3, 2022 | Jul 19, 2022before the open | $24.00B | – | $1.80 | $2.59 | Release |
| Q1 FY2022ended Apr 3, 2022 | Apr 19, 2022before the open | $23.40B | – | $1.93 | $2.67 | Release |
| Q4 FY2021ended Jan 2, 2022 | Jan 25, 2022before the open | $24.80B | – | $1.77 | $2.13 | Release |
| Q3 FY2021ended Oct 3, 2021 | Oct 19, 2021before the open | $23.30B | – | $1.37 | $2.60 | Release |
| Q2 FY2021ended Jul 4, 2021 | Jul 21, 2021before the open | – | – | – | – | Release |
| Q1 FY2021ended Apr 4, 2021 | Apr 20, 2021before the open | – | – | – | – | Release |
| Q4 FY2020ended Jan 3, 2021 | Jan 26, 2021before the open | – | – | – | – | Filing |
| Q3 FY2020ended Sep 27, 2020 | Oct 13, 2020before the open | – | – | – | – | Filing |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Current guidance
Johnson & Johnson's latest outlook for periods it has not reported yet, compared with what it said before
| Metric | Period | Guidance | Before | Change | Given |
|---|---|---|---|---|---|
| Estimated Reported SalesGAAP | FY2026 | $101.00B – $101.40B | – | New | Oct 13, 2026 |
| Estimated Reported Salesnon-GAAP | FY2026 | $100.30B – $101.30B | – | New | Apr 14, 2026 |
| Estimated Reported SalesGAAP | FY2026 | $100.00B – $101.00B | – | New | Jan 21, 2026 |
| Adjusted EPS (Diluted)non-GAAP | FY2026 | $11.05 – $11.15 | – | New | Oct 13, 2026 |
| Adjusted EPS (Diluted)non-GAAP | FY2026 | $11.45 – $11.65 | $11.43 – $11.63 | Raised | Apr 14, 2026 |
| Adjusted EPS (Diluted) Change vs. Prior Yearnon-GAAP | FY2026 | +7.5% – +8.9% | – | Raised | Jul 15, 2026 |
| Adjusted Operational EPS (Diluted) Change vs. Prior Yearnon-GAAP | FY2026 | +6.6% – +8% | – | Reaffirmed | Jul 15, 2026 |
| Estimated Reported Sales Change vs. Prior Yearnon-GAAP | FY2026 | +7% – +7.6% | – | Raised | Jul 15, 2026 |
| Operational Sales Change vs. Prior Yearnon-GAAP | FY2026 | +6.5% – +7.1% | – | New | Jul 15, 2026 |
Guidance vs results
The last range Johnson & Johnson gave before each report, against the figure it then reported. Full years add up the four quarters.
| Period | Metric | Guidance | Actual | Result |
|---|---|---|---|---|
| FY2025 | Adjusted Operational EPS (Diluted) | $10.63 – $10.73 | $10.80Σ4Q | Above range |
| FY2025 | Revenue | $93.50B – $93.90B | $94.24BΣ4Q | Above range |
| FY2025 | Revenue growth | +3.5% – +4% | +6.12%Σ4Q | Above range |
Guidance history
Every forecast Johnson & Johnson put in an earnings release, newest first
| Given | Metric | Period | Guidance | Change |
|---|---|---|---|---|
| Oct 13, 2026 | Adjusted EPS (Diluted) | FY2026 | $11.05 – $11.15 | New |
| Oct 13, 2026 | Estimated Reported Sales | FY2026 | $101.00B – $101.40B | New |
| Jul 15, 2026 | Operational Sales Change vs. Prior Year | FY2026 | +6.5% – +7.1% | New |
| Jul 15, 2026 | Estimated Reported Sales Change vs. Prior Year | FY2026 | +7% – +7.6% | Raised |
| Jul 15, 2026 | Adjusted Operational EPS (Diluted) Change vs. Prior Year | FY2026 | +6.6% – +8% | Reaffirmed |
| Jul 15, 2026 | Adjusted EPS (Diluted) Change vs. Prior Year | FY2026 | +7.5% – +8.9% | Raised |
| Apr 14, 2026 | Adjusted EPS (Diluted) | FY2026 | $11.45 – $11.65 | Raised |
| Apr 14, 2026 | Estimated Reported Sales | FY2026 | $100.30B – $101.30B | New |
| Jan 21, 2026 | Adjusted EPS (Diluted) | FY2026 | $11.43 – $11.63 | New |
| Jan 21, 2026 | Estimated Reported Sales | FY2026 | $100.00B – $101.00B | New |
| Oct 14, 2025 | Adjusted Operational EPS (Diluted) | FY2025 | $10.63 – $10.73 | Lowered |
| Oct 14, 2025 | Adjusted EPS (Diluted) | FY2025 | $10.80 – $10.90 | Raised |
| Oct 14, 2025 | Estimated Reported Sales | FY2025 | $93.50B – $93.90B | Raised |
| Oct 14, 2025 | Adjusted Operational Sales | FY2025 | +3.5% – +4% | New |
| Oct 14, 2025 | Operational Sales | FY2025 | $93.00B – $93.40B | Lowered |
| Jul 16, 2025 | Adjusted EPS (Diluted) | FY2025 | $10.80 – $10.90 | New |
| Jul 16, 2025 | Estimated Reported Sales | FY2025 | $93.20B – $93.60B | New |
| Apr 15, 2025 | Adjusted Operational Sales Change vs. Prior Year | FY2025 | +2% – +3% | New |
| Jan 22, 2025 | Adjusted Operational EPS (Diluted) | FY2025 | $10.75 – $10.95 | New |
| Jan 22, 2025 | Adjusted EPS (Diluted) | FY2025 | $10.50 – $10.70 | Lowered |
| Jan 22, 2025 | Adjusted Operational Sales Change vs. Prior Year | FY2025 | +2% – +3% | New |
| Jan 22, 2025 | Operational Sales | FY2025 | $90.90B – $91.70B | New |
| Jan 22, 2025 | Estimated Reported Sales | FY2025 | $89.20B – $90.00B | Lowered |
| Oct 15, 2024 | Adjusted Operational EPS (Diluted) | FY2024 | $9.86 – $9.96 | Lowered |
| Oct 15, 2024 | Adjusted EPS (Diluted) | FY2024 | $9.88 – $9.98 | Raised |
| Oct 15, 2024 | Estimated Reported Sales | FY2024 | $88.40B – $88.80B | New |
| Oct 15, 2024 | Operational Sales | FY2024 | $89.40B – $89.80B | Raised |
| Oct 15, 2024 | Adjusted Operational Sales Change vs. Prior Year | FY2024 | +5.7% – +6.2% | Raised |
| Jul 17, 2024 | Adjusted Operational EPS (Diluted) | FY2024 | $10.00 – $10.10 | Lowered |
| Jul 17, 2024 | Adjusted EPS (Diluted) | FY2024 | $9.97 – $10.07 | Lowered |
| Jul 17, 2024 | Adjusted Operational Sales | FY2024 | +5.5% – +6% | New |
| Jul 17, 2024 | Estimated Reported Sales | FY2024 | $88.00B – $88.40B | Reaffirmed |
| Jul 17, 2024 | Operational Sales | FY2024 | $89.20B – $89.60B | Raised |
| Apr 16, 2024 | Adjusted EPS (Diluted) | FY2024 | $10.57 – $10.72 | Narrowed |
| Apr 16, 2024 | Estimated Reported Sales | FY2024 | $88.00B – $88.40B | Narrowed |
| Apr 16, 2024 | Operational Sales | FY2024 | $88.70B – $89.10B | Raised |
| Jan 23, 2024 | Adjusted EPS (Diluted) | FY2024 | $10.55 – $10.75 | New |
| Jan 23, 2024 | Operational Sales | FY2024 | $88.20B – $89.00B | New |
| Jan 23, 2024 | Estimated Reported Sales | FY2024 | $87.80B – $88.60B | New |
| Oct 17, 2023 | Adjusted EPS (Diluted) | FY2023 | $10.07 – $10.13 | Lowered |
| Oct 17, 2023 | Estimated Reported Sales | FY2023 | $83.60B – $84.00B | Lowered |
| Jul 20, 2023 | Adjusted EPS (Diluted) | FY2023 | $10.70 – $10.80 | Raised |
| Jul 20, 2023 | Estimated Reported Sales | FY2023 | $98.80B – $99.80B | Raised |
| Apr 18, 2023 | Adjusted EPS (Diluted) | FY2023 | $10.60 – $10.70 | Raised |
| Apr 18, 2023 | Estimated Reported Sales | FY2023 | $97.90B – $98.90B | Raised |
| Jan 24, 2023 | Adjusted EPS (Diluted) | FY2023 | $10.45 – $10.65 | New |
| Jan 24, 2023 | Estimated Reported Sales | FY2023 | $96.90B – $97.90B | New |
| Oct 18, 2022 | Adjusted EPS (Diluted) | FY2022 | $10.02 – $10.07 | Narrowed |
| Oct 18, 2022 | Estimated Reported Sales | FY2022 | $93.00B – $93.50B | Lowered |
| Jul 19, 2022 | Adjusted EPS (Diluted) | FY2022 | $10.00 – $10.10 | Lowered |
| Jul 19, 2022 | Estimated Reported Sales | FY2022 | $93.30B – $94.30B | New |
| Apr 19, 2022 | Adjusted EPS (Diluted) | FY2022 | $10.15 – $10.35 | Lowered |
| Apr 19, 2022 | Estimated Reported Sales | FY2022 | $94.80B – $95.80B | New |
| Jan 25, 2022 | Adjusted EPS (Diluted) | FY2022 | $10.40 – $10.60 | New |
| Jan 25, 2022 | Estimated Reported Sales | FY2022 | $98.90B – $100.40B | New |
| Oct 19, 2021 | Adjusted EPS (Diluted) | FY2021 | $9.77 – $9.82 | New |
| Oct 19, 2021 | Estimated Reported Sales | FY2021 | $94.10B – $94.60B | New |
Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.
Adjusted figures
Non-GAAP numbers Johnson & Johnson reports itself, taken from its earnings releases
| Measure | Q3 FY2026 | Q2 FY2026 | Q1 FY2026 | Q4 FY2025 | FY2025 |
|---|---|---|---|---|---|
| Adjusted Net Earnings | $6.34B | $7.08B | $6.61B | $6.01B | $26.22B |
| adjusted EPS* | $2.59 | $2.90 | $2.70 | $2.46 | $10.79 |
| Free Cash Flow | – | $8.70B | $1.50B | – | $19.70B |
Read from the company's own earnings releases; hover a figure for the sentence it came from. Companies choose what to leave out of an adjusted number and there is no standard for it, so these are not comparable between companies the way the audited statements are. Margins here are computed from the adjusted revenue of the same period.
Press releases
Releases Johnson & Johnson filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Update
- Update
- Update
- Results
- Results
- Results
- Results
- Results
- Results
- Results
- Results
- Results
- Results
See a number that looks wrong?